Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will release its financial results for the quarter ending March 31, 2023, post-market on May 8, 2023. A conference call to discuss the results is scheduled for 4:30 PM ET on the same day. Interested participants can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. The event will also be available via live and archived webcast on the Establishment Labs investor relations webpage.
Establishment Labs specializes in medical technology focused on women's health, offering products like the Motiva® breast devices, which are backed by over 200 patents. The company operates two manufacturing facilities in Costa Rica, adhering to strict regulatory standards.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced a public offering of 1,100,000 common shares priced at $71.50, with gross proceeds estimated at $78.7 million. The offering, scheduled to close on April 27, 2023, includes a 30-day option for underwriters to purchase an additional 165,000 shares. Proceeds from the offering will be allocated for general corporate purposes, including sales and marketing, research and development, and working capital. Jefferies, J.P. Morgan, Citigroup, and TD Cowen are the joint book-running managers for this offering, which was filed under a prospectus supplement dated April 24, 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has initiated a public offering of its common shares, with a possible additional 15% for underwriters. The offering's proceeds will fund general corporate needs, including sales, marketing, research, and working capital. Market conditions will dictate the offering's completion and terms. Jefferies, J.P. Morgan, Citigroup, and TD Cowen are the joint book-running managers, while BTIG acts as co-manager. The offering materials are detailed in a prospectus supplement filed under the company's existing shelf registration.
This action reflects Establishment Labs' commitment to advancing women’s health through its innovative Femtech solutions, including the Motiva® devices. These devices have redefined safety and satisfaction standards in 85 countries.